171 related articles for article (PubMed ID: 32004612)
1. Fucoidan from Laminaria japonica exerts antitumor effects on angiogenesis and micrometastasis in triple-negative breast cancer cells.
Hsu WJ; Lin MH; Kuo TC; Chou CM; Mi FL; Cheng CH; Lin CW
Int J Biol Macromol; 2020 Apr; 149():600-608. PubMed ID: 32004612
[TBL] [Abstract][Full Text] [Related]
2. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
3. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
5. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
6. An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Zhang X; Zou G; Li X; Wang L; Xie T; Zhao J; Wang L; Jiao S; Xiang R; Ye H; Shi Y
Cancer Biol Med; 2020 Aug; 17(3):693-706. PubMed ID: 32944400
[No Abstract] [Full Text] [Related]
7. The structure property and endothelial protective activity of fucoidan from Laminaria japonica.
Chen A; Lan Y; Liu J; Zhang F; Zhang L; Li B; Zhao X
Int J Biol Macromol; 2017 Dec; 105(Pt 2):1421-1429. PubMed ID: 28754625
[TBL] [Abstract][Full Text] [Related]
8. Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
Wang P; Liu Z; Liu X; Teng H; Zhang C; Hou L; Zou X
PLoS One; 2014; 9(8):e106071. PubMed ID: 25162296
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
10. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
[TBL] [Abstract][Full Text] [Related]
11. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer.
Li QW; Zhang GL; Hao CX; Ma YF; Sun X; Zhang Y; Cao KX; Li BX; Yang GW; Wang XM
J Ethnopharmacol; 2021 Feb; 266():113430. PubMed ID: 33011366
[TBL] [Abstract][Full Text] [Related]
12. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro.
Xue M; Ji X; Xue C; Liang H; Ge Y; He X; Zhang L; Bian K; Zhang L
Biomed Pharmacother; 2017 Oct; 94():898-908. PubMed ID: 28810530
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
14. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect and molecular mechanism of fucoidan in NSCLC.
Chen X; Sun L; Wei X; Lu H; Tan Y; Sun Z; Jiang J
BMC Complement Med Ther; 2021 Jan; 21(1):25. PubMed ID: 33430854
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer.
Bimonte S; Barbieri A; Palma G; Rea D; Luciano A; D'Aiuto M; Arra C; Izzo F
Biomed Res Int; 2015; 2015():878134. PubMed ID: 25879038
[TBL] [Abstract][Full Text] [Related]
17. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
18. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
Huang Y; Fang J; Lu W; Wang Z; Wang Q; Hou Y; Jiang X; Reizes O; Lathia J; Nussinov R; Eng C; Cheng F
Cell Chem Biol; 2019 Aug; 26(8):1143-1158.e6. PubMed ID: 31178408
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
20. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]